Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Gurusamy, Kurinchi S ^a   Wilson, Edward ^b,c   Koretz, Ronald L ^d   Allen, Victoria B ^a   Davidson, Brian R ^a   Burroughs, Andrew K ^a   Gluud, Christian ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Cochrane Hepato Biliary Group ^*  (United States)

^e Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; LIFE EXPECTANCY; MORTALITY; PROGNOSIS; RELAPSE;

ANTIVIRAL AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIFE EXPECTANCY; MALE; MODELS, BIOLOGICAL; SURVIVAL RATE;

EID: 84892571704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083313     Document Type: Article

References (44)

1. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17: 107-115. doi:10.1111/j.1469-0691.2010.03432.x. PubMed: 21091831.
2. Xia X, Luo J, Bai J, Yu R (2008) Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 122: 990-1003. doi:10.1016/j.puhe.2008.01.014. PubMed: 18486955.
3. Kleinman SH, Lelie N, Busch MP (2009) Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 49: 2454-2489. doi: 10.1111/j.1537-2995.2009.02322.x. PubMed: 19682345.
4. Tohme RA, Holmberg SD (2010) Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 52: 1497-1505. doi:10.1002/hep.23808. PubMed: 20635398.
5. Syriopoulou V, Nikolopoulou G, Daikos GL, Theodoridou M, Pavlopoulou I et al. (2005) Mother to child transmission of hepatitis C virus: rate of infection and risk factors. Scand J Infect Dis 37: 350-353. doi:10.1080/ 00365540510032105. PubMed: 16051571.
6. Jafari S, Copes R, Baharlou S, Etminan M, Buxton J (2010) Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis 14: e928-e940. doi:10.1016/j.ijid.2010.03.019. PubMed: 20678951.
7. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME (2000) Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev 13: 385-407. doi:10.1128/CMR.13.3.385-407.2000. PubMed: 10885983.
8. Wawrzynowicz-Syczewska M, Kubicka J, Lewandowski Z, Boroń- Kaczmarska A, Radkowski M (2004) Natural history of acute symptomatic hepatitis type C. Infection 32: 138-143. doi:10.1007/s15010-004-3062-8. PubMed: 15188072.
9. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP et al. (2004) High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 73: 387-391. doi:10.1002/jmv.20103. PubMed: 15170633.
10. Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A et al. (2012) Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV Infection. Gastroenterology 142: 78-85. doi:10.1053/j.gastro.2011.09.039. PubMed: 22192885.
11. Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U et al. (2005) Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study. J Hepatol 43: 590-598. doi: 10.1016/j.jhep.2005. 04.007. PubMed: 16237783.
12. Seeff LB (2009) The history of the "natural history" of hepatitis C (1968-2009). Liver International 29 Suppl 1: 89-99. doi:10.1111/j.1478-3231.2008.01927.x. PubMed: 19207971.
13. Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340: 1228-1233. doi:10.1056/NEJM199904223401602. PubMed: 10210705.
14. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T et al. (2000) Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 32: 582-587. doi:10.1053/jhep.2000.9714. PubMed: 10960453.
15. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R et al. (2006) The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43: 1303-1310. doi: 10.1002/hep.21176. PubMed: 16729298.
16. Rosen HR (2011) Clinical practice. Chronic hepatitis C infection. N Engl J Med 364: 2429-2438. doi:10.1056/NEJMcp1006613. PubMed: 21696309.
17. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K et al. (2012) Long-Term Cohort Study of Chronic Hepatitis C according to Interferon Efficacy. J Gastroenterol Hepatol 27: 291-299. doi:10.1111/j.1440-1746.2011.06871.x. PubMed: 21793911.
18. Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S et al. (2010) Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat 17: 185-191. doi:10.1111/j.1365-2893.2009.01163.x. PubMed: 19709362.
19. Imazeki F, Yokosuka O, Fukai K, Saisho H (2003) Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 38: 493-502. doi:10.1016/S0270-9139(03)80733-4. PubMed: 12883494.
20. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H et al. (2000) Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 87: 741-749. doi:10.1002/1097-0215(20000901)87:5. PubMed: 10925370.
21. US Food and Drug Administration (2011) FDA approves Incivek for hepatitis C. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm256299.htm. Accessed 24 October 2011
22. Keus F, Wetterslev J, Gluud C, van Laarhoven CJ (2010) Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol 10: 90. doi:10.1186/1471-2288-10-90. PubMed: 20920306.
23. Koretz RL, Pleguezuelo M, Arvaniti V, Baena PB, Ciria R et al. (2013) Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews: CD, 1: 003617. PubMed: 23440791.
24. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA et al. (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6: 217-227. doi:10.1002/(SICI)1099-1050(199705)6:3. PubMed: 9226140.
25. Office for National Statistics (2011) Interim Life Tables, 2008-2010. Available:http://www.ons.gov.uk/ons/publications/re-referencetableshtml?edition= tcm%3A77-223324. Accessed 24 October 2011
26. HM Treasury (2003) (updated 2011)) The Green Book. Appraisal and Evaluation in Central Government. Available: http://www.hmtreasury.gov.uk/d/ green-book-complete.pdf. Accessed 24 October 2011
27. Kong Y, Wang X, Shang Y, Schroder PM, Liang W et al. (2012) Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLOS ONE 7: e52158. doi: 10.1371/journal.pone.0052158. PubMed: 23284915.
28. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB et al. (2013) Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 158: 114-123. doi:10.7326/0003-4819-158-2-201301150-00576. PubMed: 23437439.
29. Ng V, Saab S (2011) Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9: 923-930. doi:10.1016/j.cgh.2011.05.028. PubMed: 21699815.
30. Gluud C, Brok J, Gong Y, Koretz RL (2007) Hepatology may have problems with putative surrogate outcome measures. J Hepatol 46: 734-742. doi:10.1016/j.jhep.2007.01.003. PubMed: 17316871.
31. Brok J, Gluud LL, Gluud C (2010) Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews: CD: 005445. PubMed: 2009157716034976.
32. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
33. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y et al. (2004) Grading quality of evidence and strength of recommendations. BMJ 328: 1490. doi:10.1136/bmj.328.7454.1490. PubMed: 15205295.
34. Jadad AR, Cook DJ, Jones A, Klassen TP, Tugwell P et al. (1998) Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA 280: 278-280. doi:10.1001/jama.280.3.278. PubMed: 9676681.
35. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA (1999) Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an Article measuring the effect of an intervention on surrogate end points Evidence-Based Medicine Working Group. JAMA 282: 771-778
36. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C et al. (2008) A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358: 2319-2331. doi:10.1056/NEJMoa0802395. PubMed: 18480196.
37. MHRA (2007) Aprotinin (Trasylol): suspension of UK marketing authorisations (licences). Available: http://www.mhra.gov.uk/Safetyinformation/ Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2033201. Accessed 3 September 2011
38. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471. doi:10.1056/NEJMoa072761. PubMed: 17517853.
39. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P et al. (2002) Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews: CD: 000370. PubMed: 12076394.
40. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT et al. (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366: 216-224. doi:10.1056/NEJMoa1104430. PubMed: 22256805.
41. Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A et al. (2011) Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. Dig Dis Sci 56: 2449-2455. doi:10.1007/s10620-011-1770-3. PubMed: 21706207.
42. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832. doi: 10.1016/S0140-6736(96) 07642-8. PubMed: 9121257.
43. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I et al. (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 51: 788-795. doi:10.1086/656235. PubMed: 20804372.
44. Yudkin JS, Lipska KJ, Montori VM (2011) The idolatry of the surrogate. BMJ 343: d7995. doi:10.1136/bmj.d7995. PubMed: 22205706.